Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...
Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...
Regeneron (NASDAQ: REGN )'s flagship eye drug franchise, consisting of EYLEA HD and EYLEA, saw U.S. net sales increase 2% to ...
THE TV – “Feel tired? Out of energy? Then you need Oxyoxt.” “I used to have broken bones, cancer of the thumbs and nightmares ...
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...
L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback